Patents Examined by Shawquia Jackson
-
Patent number: 12378254Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.Type: GrantFiled: June 2, 2023Date of Patent: August 5, 2025Assignee: Janssen Pharmaceutica NVInventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
-
Patent number: 12377067Abstract: The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and/or frequency of ralinepag and/or riociguat, reduced doses and/or frequency of ralinepag and/or treprostinil, and reduced doses and/or frequency of ralinepag and/or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and/or iloprost monotherapies.Type: GrantFiled: November 10, 2017Date of Patent: August 5, 2025Assignees: ARENA PHARMACEUTICALS, INC.Inventors: Dominic P. Behan, John W. Adams, Lucie H. Clapp
-
Patent number: 12369583Abstract: The present invention relates to the use of N-methoxy(phenylethyl)-pyrazole carboxamides for the control of nematodes in agriculture and as antihelminthic agents against endoparasites in animals and humans, as well as compositions comprising such compounds. The present invention 5 further relates to the use of these compounds or compositions for controlling nematodes and/or helminths, in particular for controlling plant parasitic nematodes, and to the use of these compounds in preparing nematicidal and/or antihelminthic compositions.Type: GrantFiled: December 23, 2019Date of Patent: July 29, 2025Assignee: SYNGENTA CROP PROTECTION AGInventors: Domenica Jenni, Brigitte Slaats, Ana Cristina Dutton
-
Patent number: 12371405Abstract: The present invention relates to an isoindol-sulfilimine compound and its preparation and its use as a sigma-2 receptor inhibitor. Compared with the prior art, the isoindol-sulfilimine compound prepared by the present invention can effectively inhibit the sigma-2 receptor activity by binding to the sigma-2 receptor and deformationally regulating the sigma-2 receptor complex, which will lead to the instability of the binding of adjacent A? oligomers to the receptor on the synapse, thus leading to the removal of AB oligomers from the synapse. It can be further used for the preparation of new therapeutic drugs for tumor and neurodegenerative diseases.Type: GrantFiled: February 20, 2025Date of Patent: July 29, 2025Assignee: SHANGHAI UNIVERSITY OF MEDICINE AND HEALTH SCIENCESInventors: Xiuhong Lu, Gang Huang, Anyang Sun, Yongsheng Zhang, Jincheng Wang, Jinjing He
-
Patent number: 12365801Abstract: Disclosed herein, inter alia, are silicon containing detectable compounds and methods of use thereof. In an aspect is provided a monovalent nucleotide or monovalent nucleoside covalently bound to a monovalent form of a compound described herein (e.g., wherein the R13 moiety of a compound described herein has reacted with a bioconjugate reactive group to form a bioconjugate linker thereby covalently bonding the monovalent compound to the monovalent nucleotide or monovalent nucleoside).Type: GrantFiled: March 29, 2024Date of Patent: July 22, 2025Assignee: Singular Genomics Systems, Inc.Inventors: Megha Cila, Ronald Graham, Rodrigo Rodriguez
-
Patent number: 12364696Abstract: The present invention relates to methods and compositions for the treatment of autoimmune diseases and of excessive hair shedding or hair loss in a subject or for promoting hair growth in a subject wherein the subject has an autoimmune hair loss disorder, such as alopecia areata. The methods and compositions comprise the administration of a janus kinase inhibitor, such as tofacitinib, wherein the inhibitor is predominantly absorbed through the oral mucosal routes such as the sublingual mucosa.Type: GrantFiled: February 27, 2020Date of Patent: July 22, 2025Assignee: JAK Slave Pty LtdInventors: Rodney Sinclair, Yuk-Shui Andrew Lau
-
Patent number: 12357632Abstract: Provided herein are methods of treating advanced or metastatic cholangiocarcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof, wherein the patient has progression of the cholangiocarcinoma after previous administration of another therapy.Type: GrantFiled: May 28, 2020Date of Patent: July 15, 2025Assignee: QED Therapeutics, Inc.Inventors: Riccardo Panicucci, Michael Monteith, Gang Li, Susan Arangio, Craig Berman, Michael Howland, Daniel Mulreany, Carl Dambkowski
-
Patent number: 12358878Abstract: An N-aromatic amide compounds with formula (I) is disclosed. The definitions of R1, R2, R3, R4, R5, R6, W1, W2 and W3 in the formula are the same as those in the description.Type: GrantFiled: July 28, 2023Date of Patent: July 15, 2025Assignee: Shenzhen EDK Pharmaceutical Technology Co., Ltd.Inventors: Guohong Yang, Lijun Yu, Junze He, Meijuan Duan
-
Patent number: 12351554Abstract: The present disclosure provides a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. Solvent screen, X-ray powder diffractogram, thermogravimetric mass spectroscopy, differential scanning calorimetry, 1H-NMR, dynamic vapor sorption, and UPLC data on each of the crystalline forms is presented, along with methods preparing each of the crystalline forms.Type: GrantFiled: June 13, 2024Date of Patent: July 8, 2025Assignee: Zylorion Health, Inc.Inventor: Peter Silverstone
-
Patent number: 12344617Abstract: Provided is a photochromic indolenaphthopyran compound having the skeletal structure of Formula (I): wherein R1 and R2 each independently have a steric bulk A, wherein at least one of R1 or R2 has a steric bulk A of at least 0.6, R3 and R4 each independently have a Hammett ?p value, and wherein the indolenaphthopyran compound has a calculated electronic steric factor of at least ?3.3.Type: GrantFiled: December 21, 2018Date of Patent: July 1, 2025Assignee: Transitions Optical, Ltd.Inventors: Ryan Stayshich, Darrin R. Dabideen, Zachary Smith, Robert W. Walters
-
Patent number: 12342823Abstract: The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound of the formula (II), which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarids and/or unwanted nematodes.Type: GrantFiled: December 16, 2019Date of Patent: July 1, 2025Assignee: Bayer AktiengesellschaftInventors: Stefan Herrmann, Reiner Fischer, Marita John
-
Patent number: 12344620Abstract: Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I).Type: GrantFiled: March 23, 2020Date of Patent: July 1, 2025Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.Inventors: Chunli Shen, Yong Liu, Huanyu Bian, Chengde Wu, Jiahu Wu
-
Patent number: 12338230Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.Type: GrantFiled: January 22, 2024Date of Patent: June 24, 2025Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang, William Greenlee
-
Patent number: 12297168Abstract: This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).Type: GrantFiled: March 7, 2023Date of Patent: May 13, 2025Assignee: ABIONYX PHARMA SAInventor: Jean-Louis Henri Dasseux
-
Patent number: 12295962Abstract: The present invention provides co-crystal and salt forms, and compositions and methods thereof, useful for treating various diseases, disorders or conditions in which EP4 prostaglandin receptors are implicated in the mediation of a proliferative disorder, by the administration of small molecule therapeutics acting as inhibitors of prostaglandin EP4 receptor activity.Type: GrantFiled: April 2, 2024Date of Patent: May 13, 2025Assignee: AskAt Inc.Inventors: Alfredo C. Castro, David T. Jonaitis
-
Patent number: 12291499Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.Type: GrantFiled: March 8, 2024Date of Patent: May 6, 2025Assignee: Cybin IRL LimitedInventor: Alex Nivorozhkin
-
Patent number: 12291503Abstract: The present disclosure relates to the field of pharmaceutical technology, providing three crystalline forms, i.e., a crystalline form AB, a crystalline form M and a crystalline form F, of the compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminoformyl]cyclopropanecarbonyl]-amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoic acid for treatment of diseases related to protein kinases AXL and/or VEGFR2. The present disclosure also provides methods for preparing these three crystalline forms and pharmaceutical compositions comprising these three crystalline forms. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure all have good chemical stability, and the preparation processes of the three crystalline forms of the present disclosure are simple for implementation with high product yield and purity, allowing stable and mass production that facilitates promotion and application.Type: GrantFiled: April 20, 2020Date of Patent: May 6, 2025Assignee: Beijing Konruns Pharmaceutical Co., Ltd.Inventors: Xiaohua Sun, Long Wang, Hongzhen Yang, Huaizhong Hu
-
Patent number: 12286398Abstract: Provided herein are novel antibacterial compounds of Formula I. The compounds can be made through enzymatic oxidative dimerization in the presence of a suitable organism and one or more metal salts. Pathogenic bacteria exposed to the compound of Formula I do not develop resistance to these compounds even after prolonged exposure. Also provided herein are methods of treating bacterial infections, and method of killing or disinfecting bacteria.Type: GrantFiled: April 17, 2020Date of Patent: April 29, 2025Assignee: Yale UniversityInventors: Jason Crawford, Tyler Goddard, Hyun Bong Park, Jaymin Patel
-
Patent number: 12281102Abstract: The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.Type: GrantFiled: June 11, 2021Date of Patent: April 22, 2025Assignee: Vertex Pharmaceuticals IncorporatedInventors: Leslie A. Dakin, Timothy J. Senter, Jingrong Cao, Jon H. Come, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Francois Maltais, Suganthini S. Nanthakumar, Olivier Nicolas, Camil E. Sayegh, Tiansheng Wang, Stephanie Dorich, Lee Fader, Claudio Sturino, Janek Szychowski
-
Patent number: 12280028Abstract: The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.Type: GrantFiled: March 29, 2021Date of Patent: April 22, 2025Assignee: SEN-JAM PHARMACEUTICAL INC.Inventors: Jacqueline M. Iversen, Thomas A. Dahl